Recent studies have enhanced our understanding of the role of the SIRT1 deacetylase in regulation of normal hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs), and its importance in regulating autophagy and epigenetic reprogramming in response to metabolic alterations.
INTRODUCTION
Silent information regulator-2 (Sir-2) proteins, or sirtuins, are a highly conserved protein family of nicotinamide adenosine dinucleotide (NAD)dependent histone deacetylases (class III histone deacetylases and SIRT1-7) that promote longevity and are conserved from lower organisms to mammalian cells [1 & ]. Mammalian sirtuins are recognized as critical regulators of cellular stress resistance, energy metabolism and tumorigenesis. There are seven mammalian sirtuins that exhibit distinct expression patterns, catalytic activities and biological functions. SIRT1 shares the highest homology with yeast Sir-2 and is the most extensively studied of the sirtuins. In addition to its roles in gene silencing and heterochromatin formation, related to histone H4K16 and H1K26 deacetylation, SIRT1 also deacetylates several nonhistone proteins to regulate a variety of biological processes including cell growth, apoptosis and adaptation to calorie restriction, metabolism and cell senescence [2] . Interestingly, both tumor suppressors and oncogenes can be modulated by SIRT1 deacetylation, and SIRT1 can function as a tumor suppressor or oncogene depending on the specific cancer type [3] .
Previous studies have indicated a potential role of SIRT1 in embryonic hematopoiesis, in adult hematopoiesis under hypoxia, and in regulation of leukemic hematopoiesis through regulation of p53 activity [4, 5] . The current review summarizes recent studies that enhance our understanding the role of SIRT1 in regulation of normal hematopoietic stem cells (HSCs) under conditions of stress, in maintenance and drug resistance of leukemia stem cells (LSCs), and in regulating autophagy and
The role of SIRT1 in regulation of normal hematopoietic stem cells HSCs are characterized by capacity for both extensive self-renewal as well as generation of hematopoietic cells of different lineages. Several studies have evaluated the role of SIRT1 in normal HSC regulation. SIRT1 inhibition by RNA interference (RNAi) or a pharmacological inhibitor had only a minor impact on normal human CD34 þ hematopoietic cells or CD34 þ CD38 À primitive progenitors [4] . SIRT1 knockout mouse models have been established, and although significant embryonic or perinatal mortality is seen, a fraction of mice survive to adulthood. Previous studies showed that SIRT1 regulates apoptosis expression in mouse embryonic stem cells (ESCs) by controlling p53 subcellular localization and that SIRT1 À/À ESCs formed fewer mature blast cell colonies, and SIRT1 À/À yolk sacs manifested fewer primitive erythroid precursors [5, 6] . These results support an important role of SIRT1 during embryonic hematopoietic development. Adult SIRT1 À/À mice demonstrated the decreased numbers of bone marrow hematopoietic progenitors. Hematopoietic defects were more apparent under hypoxic rather than normoxic condition. Matsui et al. [7] observed that SIRT1 was widely expressed in human and murine hematopoietic cells of all lineages and stages of maturation. HSCs from SIRT1 À/À mice showed enhanced differentiation and loss of stem cell characteristics, suggesting that SIRT1 suppresses HSC differentiation and contributes to the maintenance of the HSC pool. HSC maintenance was related to reactive oxygen species (ROS) elimination, Forkhead box subgroup O (FOXO) activation and p53 inhibition. On the contrary, Leko et al. [8] reported that SIRT1 exon 4 deleted C57BL/6 mice, which exhibit all of the stigmata of SIRT1 deletion, did not exhibit any phenotypic or functional abnormalities in their HSC compartment. HSCs from young SIRT1-deficient mice were capable of stable long-term reconstitution in competitive repopulation and serial transplantation experiments, arguing against an essential role of SIRT1 in HSC maintenance in adult mice, at least in a steady state.
A conditional deletion approach has recently been used to further evaluate the role of SIRT1 in HSC homeostasis. Rimmele et al. [9 && ] using a tamoxifen-inducible SIRT1 knockout mouse model showed that SIRT1 deletion was associated with anemia, expansion of myeloid cells and depletion of lymphoid cells. These phenotypic changes were combined with DNA damage accumulation and gene expression changes associated with aging, suggesting that SIRT1-deleted HSCs demonstrated features associated with aging. Their studies suggested an important role for transcription factor FOXO3 in mediating the homeostatic effects of SIRT1 in HSCs. Singh et al. [10 && ] showed that SIRT1 deletion in the tamoxifen-inducible model resulted in increased cycling and aberrant expansion of hematopoietic stem/progenitor cells in vivo. On the contrary, constitutive SIRT1 ablation using Vav-Cre specific to hematopoietic cells resulted with the progressive loss of HSCs but only in the context of hematopoietic stress. SIRT1 loss was associated with the accumulation of DNA damage and genomic aberrations. SIRT1 physically associated with and negatively regulated the Hoxa9 gene, a key HSC regulator. Together, these findings indicate that SIRT1 contributes to HSC maintenance under conditions of stress.
SIRT1 dysregulation in leukemia stem cells
Several leukemias including chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are propagated by small populations of LSCs that resist elimination by conventional and targeted therapies. It was previously shown that SIRT1 protein and RNA levels are significantly increased in CML compared with normal HSPC [4] . Li et al. [11 && ] showed that the majority of AML CD34 þ CD38 À cells showed increased SIRT1 expression compared with normal counterparts from healthy donors. Unlike CML, AML is a heterogeneous disease, with a number of distinct genetic abnormalities described. SIRT1 expression was
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higher in cells from patients with poor and intermediate risk genetic lesions as compared with better risk genetic lesions. An internal tandem duplication (ITD) in the Fms-like tyrosine kinase (FLT3) mutation is the most commonly observed mutation in AML, seen in 25-30% of AML patients [12] . SIRT1 protein but not mRNA expression is increased in CD34 þ cells from FLT3-ITD positive AML patients compared with FLT3 wild-type AML patients. Enhanced SIRT1 protein expression was seen after enforced expression of FLT3-ITD in normal human CD34 þ cells compared with FLT3 wild-type transduced cells. Sasca et al. [13 && ] suggested that SIRT1 modulation by FLT3-ITD was mediated by the ATM-DBC1-SIRT1 axis. However, recent studies suggest that DBC1 may function independent of SIRT1 by directly binding and stabilizing p53 [14] . Li et al. [11 && ] showed that SIRT1 overexpression in FLT3-ITD positive AML cells resulted from reduced protein degradation, related to a novel avian myelocytomatosis viral oncogene homolog c-MYCassociated posttranscriptional regulatory network. Significant enrichment of c-MYC-related genes was seen in FLT3-ITD compared with FLT3 wild-type AML blasts. Overexpression of c-MYC resulted in SIRT1 deubiquitination, whereas c-MYC knockdown led to decrease in SIRT1 protein stability and expression. USP22 deubiquitinase was overexpressed in FLT3-ITD positive AML CD34 þ cells. USP22 expression was regulated by c-MYC and contributed to c-MYC-mediated reduction in SIRT1 polyubiquitination and degradation. USP22 directly interacted with and removed polyubiquitin chains from SIRT1 to increase SIRT1 protein stabilization and expression. These results support a role of USP22 in MYC-mediated increase in SIRT1 protein stabilization, and indicate that FLT3-ITD, c-MYC and USP22 form an oncogenic network that enhances SIRT1 expression and activity in leukemic cells.
Role of SIRT1-mediated regulation of p53 in leukemia stem cell maintenance
The p53 protein plays a critical role in the cellular response to stress, by inducing cell cycle arrest or apoptosis. Loss of p53 function is a common feature of human malignancies. p53 inactivation is also required for maintenance of established malignancies, in the setting of continued oncogenic stress. In addition to mutations, p53 transcriptional activity can be modulated via posttranslational modifications. Acetylation of p53 modulates protein stability and transcriptional activity independent of phosphorylation status [15] . Deacetylation of p53 at lysine sites by SIRT1 negatively regulates p53 transcriptional activity [2] .
CML results from breakpoint cluster regionabelson murine virus homolog (BCR-ABL) oncogene transformed normal HSCs. Although BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in inducing remission in CML, they do not eliminate CML LSCs even in responsive patients, and leukemia usually recurs when treatment is stopped [16] . It was previously shown that pharmacological inhibition of SIRT1, or RNAi of SIRT1 in CML CD34 þ cells resulted in increased p53 acetylation and transcriptional activation, and increased CML CD34 þ cells apoptosis and reduced CML CD34 þ cells growth in vitro and in vivo [4, 17] . SIRT1 inhibition further enhanced targeting of CML CD34 þ cells in combination with the BCR-ABL TKI. These inhibitory effects of SIRT1 targeting on CML cells were dependent on p53 expression and acetylation.
Similar to CML, AML is hierarchically organized with small populations of self-renewing LSCs that generate the bulk of leukemic cells. Small molecule FLT3 TKIs inhibit growth but do not effectively induce apoptosis of human FLT3-ITD positive AML LSCs. In contrast to CML, TKIs demonstrate limited clinical activity in FLT3-ITD positive AML patients [12] . Li et al. [11 && ] reported that SIRT1 overexpression in FLT3-ITD AML LSCs is associated with downmodulation of p53 activity. AML cells bearing the FLT3-ITD mutation demonstrated increased sensitivity to SIRT1 inhibition [11 && ,13 && ]. SIRT1 inhibition using RNAi or the small molecule inhibitor Tenovin-6 (TV-6) enhanced acetylated p53 levels and p53 target gene expression. The inhibitory effects of TV-6 on FLT3-ITD positive CD34 þ cells are to a greater extent than FLT3 wild-type AML and normal CD34 þ cells. The combination of SIRT1 inhibition and FLT3 TKI treatment resulted in significantly increased inhibition of survival and in-vivo growth of FLT3-ITD positive AML CD34 þ cells compared with either drug alone. These results indicate a role of SIRT1-mediated inhibition of p53 activity in maintenance of AML LSC in the setting of FLT3-ITD-induced oncogenic stress [11 && ]. Interestingly, SIRT1 activation was not a feature of AML cells with FLT3-tyrosine kinase domain mutation mutations, which have different signaling and transformative properties than FLT3-ITD mutations. Sasca et al. [13 && ] also showed that leukemic blasts in murine MLL-AF9 or AML1-ETO leukemia models coexpressing FLT3-ITD become dependent on SIRT1 activity to counteract oncogene-induced stress. Pharmacologic-mediated or RNAi-mediated SIRT1 inhibition reduced cell growth and sensitized AML cells to TKI treatment and chemotherapy through restoration of p53 activity. These results further support targeting of SIRT1 as a therapeutic strategy in defined subsets of patients with AML, like FLT3-ITD positive patients.
In addition to p53, SIRT1 can also deacetylate several other proteins that regulate cell growth and survival. The role of additional SIRT1 targets in LSC transformation and drug resistance requires further investigation. SIRT1 appears to be an attractive molecular target against FLT3-ITD positive AML LSCs, and small molecule inhibitors of SIRT1 are being investigated as potential anticancer treatments [18] . Further studies to determine the spectrum and nature of oncogenic stimuli that induce SIRT1 activation and sensitivity to SIRT1 inhibition will be helpful to identify other malignancies that may benefit from SIRT1 inhibitors treatment.
The role of SIRT1 in mutagenesis SIRT1 may also play a role in leukemia evolution and drug resistance by promoting genetic instability. Wang et al. [19] showed that inhibition of SIRT1 by small molecule inhibitors or gene knockdown blocked acquisition of BCR-ABL secondary mutations in CML cells treated with TKI. SIRT1 knockdown also suppressed de-novo mutations of the hypoxanthine phosphoribosyl transferase gene in CML and non-CML cells following camptothecin treatment. Acquisition of genetic mutations was associated with SIRT1 stimulation of error-prone DNA damage repair activity. The same group subsequently showed that all-trans retinoic acid (ATRA) induced expression of CD38, a cell surface marker and cellular NADase, inhibited the activity of SIRT1 by reducing intracellular NAD þ levels [20 & ]. SIRT1 inhibition following ATRA treatment decreased DNA damage repair and suppressed acquisition of BCR-ABL secondary mutations. This study suggested a potential benefit of combining ATRA with TKIs in treating CML, particularly in advanced phases. In leukemia stem cells, SIRT1 can be upregulated by mutant tyrosine kinases through an activation of c-MYC leading to an increased expression of the USP22 deubiquitinase with reduces SIRT1 degradation. SIRT1 activation also stabilizes c-MYC leading to a feed-forward loop enhancing SIRT1 expression. Increased SIRT1 expression and activity results in deacetylation and deactivation of p53, contributing to leukemia evolution, maintenance and drug resistance. HSC, hematopoietic stem cell; NAD, nicotinamide adenosine dinucleotide; ROS, reactive oxygen species.
Role of SIRT1 in regulating autophagy in stem cells
showed that LC3, a key initiator of autophagy, is selectively activated in the nucleus during starvation through deacetylation by SIRT1. Deacetylation of LC3 allows it to return to the cytoplasm, binds Atg7 and other autophagy factors, and promote autophagy to help cope with the lack of external nutrients. Tang et al.
[23 & ] found that SIRT1 regulates autophagic flux in muscle stem cell progeny. Autophagy was induced during muscle stem cell activation. SIRT1 deficiency leads to delayed muscle stem cell activation that was partially rescued by exogenous pyruvate, supporting the importance for SIRT1 regulation of autophagy in meeting bioenergetic demands during muscle stem cell activation.
Role of SIRT1 in epigenetic reprogramming of stem cells
SIRT1 deacetylase activity is known to contribute to gene silencing and heterochromatin formation via histone H4K16 and H1K26 deacetylation. Recent studies reveal additional mechanisms and roles of SIRT1 in chromatin regulation in stem cells. The mixed-lineage leukemia 1 (MLL1) gene is responsible for H3K4 trimethylation at circadian promoters. Aguiar-Amal et al. [24 & ] showed that SIRT1 controlled MLL1-mediated H3K4 trimethylation through circadian deacetylation of the protein. MLL1 is deacetylated by SIRT1 at K1130 and K1133, leading to modulation of its methyltransferase activity. MLL-mediated H3K4 methylation at clock-controlled-gene promoters is affected by inactivation of SIRT1, which also depends on circadian levels of NAD þ . These findings indicate that SIRT1 in addition to effects on histone acetylation could also impact alterations in histone methylation in response to energy metabolism.
Mishra et al. [25 & ] found that deletion of MLL1 selectively depletes histone H4K16 acetylation at MLL1 target genes, together with reduced gene transcription. Endogenous MLL1 histone methyltransferase activity was not required for HSC gene expression and MLL-AF9 transformation. Inhibition of SIRT1 prevents loss of H4K16 acetylation and the reduction in MLL1 target gene expression. This result indicated MLL1-recruited H4K16Ac activity as the major mechanism by which gene expression is maintained in hematopoietic stem/progenitors, and SIRT1 as an antagonist for MLL1-dependent gene activation.
The studies of Ryall et al.
] showed a role of SIRT1 in integrating muscle stem cell metabolism with epigenetic changes required for myogenic commitment. During transition from quiescence to proliferation, skeletal muscle stem cells undergo a metabolic switch from fatty acid oxidation to glycolysis. This metabolic reprogramming leads to a decrease in NAD þ levels and SIRT1 activity, resulting in elevated H4K16 acetylation and activation of muscle gene transcription. These observations support a role of SIRT1 in translating metabolic cues into epigenetic modifications that regulate stem cell fate. A role of SIRT1 in linking metabolism to HSC fate has not as yet been described.
CONCLUSION
Current understanding of SIRT1 in normal hematopoiesis indicates an important role in maintaining HSC homeostasis under the hematopoietic stress (Fig. 1 ). There is also an increasing appreciation of the role of SIRT1 in regulating stem cell fate determination, and in coordinating cellular responses to metabolic cues. Previous studies demonstrating an important role of SIRT1 overexpression in maintaining CML LSCs have been extended to AML, and have revealed aberrant activation of SIRT1 in LSCs from AML patients with the common FLT3-ITD mutation, through posttranscriptional mechanism mediated by an MYC-associated oncogenic network (Fig. 1) . SIRT1 activation promotes maintenance and TKI resistance of FLT3-ITD AML LSCs. These observations support further investigation of SIRT1 inhibition as a strategy to target CML and FLT3-ITD leukemia. Further evaluations of the spectrum and nature of oncogenic stimuli that induce SIRT1 activation and sensitivity to SIRT1 inhibition and identification of other malignancies that may benefit from SIRT1 inhibitor treatment are warranted. 
